CN1890241A - A2b腺苷受体拮抗剂 - Google Patents

A2b腺苷受体拮抗剂 Download PDF

Info

Publication number
CN1890241A
CN1890241A CNA200480031969XA CN200480031969A CN1890241A CN 1890241 A CN1890241 A CN 1890241A CN A200480031969X A CNA200480031969X A CN A200480031969XA CN 200480031969 A CN200480031969 A CN 200480031969A CN 1890241 A CN1890241 A CN 1890241A
Authority
CN
China
Prior art keywords
optionally substituted
dione
pyrimidine
dihydropyrimidine
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200480031969XA
Other languages
English (en)
Chinese (zh)
Inventor
拉奥·卡拉
埃尔法蒂赫·埃尔扎因
蒂姆·马夸特
佩里涛
李晓芬
杰夫·扎布沃茨基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN1890241A publication Critical patent/CN1890241A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA200480031969XA 2003-10-31 2004-10-26 A2b腺苷受体拮抗剂 Pending CN1890241A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51601903P 2003-10-31 2003-10-31
US60/516,019 2003-10-31

Publications (1)

Publication Number Publication Date
CN1890241A true CN1890241A (zh) 2007-01-03

Family

ID=34549473

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200480031969XA Pending CN1890241A (zh) 2003-10-31 2004-10-26 A2b腺苷受体拮抗剂

Country Status (13)

Country Link
US (1) US7449473B2 (enExample)
EP (1) EP1678181B1 (enExample)
JP (1) JP4863876B2 (enExample)
KR (1) KR20060111467A (enExample)
CN (1) CN1890241A (enExample)
AT (1) ATE419252T1 (enExample)
AU (1) AU2004285013A1 (enExample)
BR (1) BRPI0415888A (enExample)
CA (1) CA2544193C (enExample)
DE (1) DE602004018808D1 (enExample)
ES (1) ES2318363T3 (enExample)
MX (1) MXPA06004789A (enExample)
WO (1) WO2005042534A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
ES2387653T3 (es) * 2004-09-01 2012-09-27 Gilead Sciences, Inc. Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B
MX2007004373A (es) 2004-10-15 2007-08-08 Cv Therapeutics Inc Metodo para prevenir y tratar el remoldeo de las vias respiratorias e inflamacion pulmonar utilizando antagonistas de receptor adenosina a2b.
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EP2301937A1 (en) * 2005-06-16 2011-03-30 Cv Therapeutics, Inc. Prodrugs of A2b adenosine receptor antagonists
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
EP1989210A2 (en) * 2006-03-02 2008-11-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
EP2029603A1 (en) * 2006-06-05 2009-03-04 Astra Zeneca AB Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
US7470697B2 (en) * 2006-09-01 2008-12-30 Adenosine Therapeutics, Llc Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors
GB0718434D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
TW200938200A (en) * 2007-12-28 2009-09-16 Dainippon Sumitomo Pharma Co Methyl-substituted piperidine derivative
CA2718983C (en) 2008-03-26 2015-12-08 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
WO2010009194A1 (en) * 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
EP2405917B1 (en) 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
US8815858B2 (en) * 2010-05-21 2014-08-26 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
CN103261200B (zh) 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
CA2862263C (en) 2011-12-27 2016-09-06 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2015003881A1 (en) * 2013-07-08 2015-01-15 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
PT4122926T (pt) * 2021-04-14 2025-07-29 Shionogi & Co Derivados de triazina com atividade inibitória da replicação de vírus e composição farmacêutica que compreende os mesmos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
WO2001094350A1 (en) 2000-06-07 2001-12-13 Almirall Prodesfarma S.A. 6-phenylpyrrolopyrimidinedione derivatives
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
WO2003006465A1 (en) * 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors
NZ532816A (en) 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists

Also Published As

Publication number Publication date
JP4863876B2 (ja) 2012-01-25
WO2005042534A3 (en) 2005-08-25
CA2544193C (en) 2012-03-27
MXPA06004789A (es) 2006-07-03
KR20060111467A (ko) 2006-10-27
US7449473B2 (en) 2008-11-11
EP1678181A2 (en) 2006-07-12
ES2318363T3 (es) 2009-05-01
CA2544193A1 (en) 2005-05-12
AU2004285013A1 (en) 2005-05-12
US20050119287A1 (en) 2005-06-02
EP1678181B1 (en) 2008-12-31
DE602004018808D1 (de) 2009-02-12
JP2007509947A (ja) 2007-04-19
WO2005042534A2 (en) 2005-05-12
ATE419252T1 (de) 2009-01-15
BRPI0415888A (pt) 2007-01-09

Similar Documents

Publication Publication Date Title
CN1890241A (zh) A2b腺苷受体拮抗剂
CN1149215C (zh) 苯基黄嘌呤衍生物
CN1042730C (zh) 吡唑并吡啶化合物的制备方法
CN1146566C (zh) 2-芳基-8-氧代二氢嘌呤衍生物及其制备方法、含该衍生物的药物组合物、及其中间体
CN1166666C (zh) 缩合咪唑化合物和治疗糖尿病的药物
CN1198825C (zh) 8－苯基－6,9－二氢－[1,2,4]三唑并[3,4－i]嘌呤－5－酮衍生物
CN1324015C (zh) 吡啶－和嘧啶－衍生物
CN1882588A (zh) A2b腺苷受体拮抗剂
CN1585769A (zh) A2b腺苷受体拮抗剂
CN101039677A (zh) 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
CN1771250A (zh) 作为a2b腺苷受体拮抗剂的黄嘌呤衍生物
CN1781920A (zh) 多环鸟嘌呤磷酸二酯酶v抑制剂
CN1538972A (zh) 腺苷a3受体激动剂
CN1703405A (zh) 用作糖原合酶激酶3β抑制剂的氨基苯甲酰胺衍生物
CN1460105A (zh) 黄嘌呤磷酸二酯酶v抑制剂
CN1071164A (zh) 含氮杂环化合物
CN1882586A (zh) 用于治疗蛋白激酶依赖性疾病的1h－咪唑并[4,5－c]喹啉衍生物
CN1784409A (zh) 具有crf活性的稠合的嘧啶衍生物
CN1503793A (zh) N-取代的非芳基-杂环nmda/nr2b拮抗剂
CN1882591A (zh) 具有PDE－5抑制活性的5,7－二氨基吡唑并[4,3－d]嘧啶
CN1656075A (zh) 喹啉衍生物和其作为5－ht6配体的用途
CN1849325A (zh) 可抑制蛋白激酶的噻唑并、噁唑并和咪唑并喹唑啉化合物
CN1585771A (zh) 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
CN1030587A (zh) 2-(杂环烷基)咪唑并吡啶
CN1352644A (zh) 抑制磷酸二酯酶IV的1－氨基三唑并[4,3－α]喹唑啉－5酮类化合物和/或－5－硫酮类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication